title: [Surgery and invasive procedures in patients on long-term treatment with oral direct thrombin or factor Xa inhibitors].
abstract: Direct oral anticoagulants (DOAs), inhibitors of factor IIa or Xa, are expected to replace vitamin K antagonists in most of their indications. It is likely that patients on long-term treatment with DOAs will be exposed to elective or emergency surgery or invasive procedures. Due to the present lack of experience in such conditions, we cannot make recommendations, but only propose perioperative management for optimal safety as regards the risk of bleeding and thrombosis. DOAs may increase surgical bleeding, they have no validated antagonists, they cannot be monitored by simple, standardised laboratory assays, and their pharmacokinetics vary significantly from patient to patient. Although DOAs differ in many respects, the proposals in the perioperative setting need not be specific to each. For procedures with low risk of haemorrhage, a therapeutic window of 48 h (last administration 24h before surgery, restart 24h after) is proposed. For procedures with medium or high haemorrhagic risk, we suggest stopping DOAs 5 days before surgery to ensure complete elimination of the drug in all patients. The treatment should be resumed only when the risk of bleeding has been controlled. In patients with a high risk of thrombosis (e.g. those in atrial fibrillation with an antecedent of stroke), bridging with heparin (low molecular weight, or unfractionated if the former is contraindicated) is proposed. In emergency, the procedure should be postponed for as long as possible (minimum 1-2 half-lives) and non-specific anti-haemorrhagic agents, such as recombinant human activated factor VIIa, or prothrombin concentrates, should not be given for prophylactic reversal, due to their uncertain benefit-risk.
authors.affiliation: Laboratoire d'hématologie, hôpital Rangueil, CHU de Toulouse, 1, avenue du Pr-Jean-Poulhès, TSA 50032, 31059 Toulouse cedex, France. sie.p@chu-toulouse.fr
authors.forename: P
authors.initials: P
authors.lastname: Sié
authors.forename: C-M
authors.initials: CM
authors.lastname: Samama
authors.forename: A
authors.initials: A
authors.lastname: Godier
authors.forename: N
authors.initials: N
authors.lastname: Rosencher
authors.forename: A
authors.initials: A
authors.lastname: Steib
authors.forename: J-V
authors.initials: JV
authors.lastname: Llau
authors.forename: P
authors.initials: P
authors.lastname: van der Linden
authors.forename: G
authors.initials: G
authors.lastname: Pernod
authors.forename: T
authors.initials: T
authors.lastname: Lecompte
authors.forename: I
authors.initials: I
authors.lastname: Gouin-Thibault
authors.forename: P
authors.initials: P
authors.lastname: Albaladejo
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000037:antagonists & inhibitors / Q000627:therapeutic use*; D065427:Factor Xa Inhibitors; D006470:Hemorrhage / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D012306:Risk; D013514:Surgical Procedures, Operative; D013917:Thrombin / Q000037:antagonists & inhibitors*; D013927:Thrombosis / Q000453:epidemiology / Q000209:etiology
chemical_list: D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D013917:Thrombin